|
Lawyers Disagree on Wyeth v. Levine (4/24/09)The recent Supreme Court decision in the case of Wyeth v. Levine, in which the plaintiff
won a tort case against the drug manufacturer for a severe adverse event — despite clear label warnings and a “preemption”
defense — will either result in burdensome, unreadable product labels to cover every possible adverse contingency associated
with use of drug products ... or it won’t. The court’s decision will either result in FDA receiving a rush of
changes being effected (CBE) supplements to product labels as a defensive measure against all possible future tort actions
... or it won’t. (read more)
|
|
 |
|
| We bring the FDA to you |
|
|
| click image to view available FDA meetings |
Our Subscription Newsletters:
|
|
| Daily FDA and Industry Regulatory and Compliance News |
|
|
| The most authoritative FDA news analysis each month |
|
|
| Weekly easy to ready news capsules |
|
